We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

129 hedge funds and large institutions have $340M invested in Karyopharm Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $515K

73% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 30

2% more capital invested

Capital invested by funds: $334M → $340M (+$5.77M)

0.65% less ownership

Funds ownership: 5.79% → 5.15% (-0.65%)

16% less funds holding

Funds holding: 154 → 129 (-25)

58% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 43

Holders
129
Holders Change
-25
Holders Change %
-16.23%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
52
Reduced
30
Closed
43
Calls
$1.03M
Puts
$515K
Net Calls
+$519K
Net Calls Change
-$184K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$7.59M
2
State Street
State Street
Massachusetts
+$6.22M
3
Barclays
Barclays
United Kingdom
+$5.93M
4
OM
Opaleye Management
Massachusetts
+$5.28M
5
SCM
Silverarc Capital Management
Massachusetts
+$5.07M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$13.1M
2
RCMNY
Rubric Capital Management (New York)
New York
-$12.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.77M
4
CC
Commodore Capital
New York
-$6.58M
5
ITP
Iron Triangle Partners
Connecticut
-$6.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$2.14M +$795K +16,109 +78%
ACM
27
Altium Capital Management
New York
$1.97M +$1.66M +33,719 New
TC
28
Tejara Capital
United Kingdom
$1.95M – – –
Alyeska Investment Group
29
Alyeska Investment Group
Illinois
$1.87M – – –
AAA
30
Affinity Asset Advisors
New York
$1.79M -$659K -13,352 -30%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.77M +$71K +1,439 +5%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$1.56M -$993K -20,113 -43%
Macquarie Group
33
Macquarie Group
Australia
$1.48M – – –
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$1.44M -$178K -3,601 -13%
IC
35
Ikarian Capital
Texas
$1.17M +$987K +20,000 New
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$1.15M +$132K +2,666 +16%
BC
37
Birchview Capital
Vermont
$1.13M – – –
Ameriprise
38
Ameriprise
Minnesota
$1M +$306K +6,191 +56%
AA
39
AlphaCentric Advisors
Puerto Rico
$934K +$790K +16,000 New
CANY
40
Caxton Associates (New York)
New York
$917K +$526K +10,646 +210%
Wellington Management Group
41
Wellington Management Group
Massachusetts
$910K +$17.9K +362 +2%
Swiss National Bank
42
Swiss National Bank
Switzerland
$901K -$90.8K -1,840 -11%
Charles Schwab
43
Charles Schwab
California
$866K +$52.2K +1,058 +8%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$768K +$617K +12,492 +1,864%
DCM
45
DAFNA Capital Management
California
$750K – – –
JP Morgan Chase
46
JP Morgan Chase
New York
$742K -$4.25M -86,100 -87%
Connor, Clark & Lunn Investment Management (CC&L)
47
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$729K -$806K -16,322 -57%
AllianceBernstein
48
AllianceBernstein
Tennessee
$692K +$65.2K +1,320 +13%
Wells Fargo
49
Wells Fargo
California
$652K +$551K +11,168 +139,600%
PA
50
Profund Advisors
Maryland
$652K +$551K +11,168 New
1
2
3 4 5

KPTI Hedge Fund Activity: Q1 2023 in Review

129 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2023, worth a combined $340M — up 1.7% from $334M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of KPTI and 18 opened new positions — a net loss of 25 holders — while 30 trimmed existing stakes and 52 added.

The largest buyer was Vanguard Group, adding an estimated $7.59M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.1M sold.

  • 129 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2023, down from 154 in Q4 2022.
  • Funds reported $340M of Karyopharm Therapeutics stock for Q1 2023, up 1.7% quarter-over-quarter.
  • 18 funds opened new Karyopharm Therapeutics positions in Q1 2023 and 43 closed out, a net change of -25 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $7.59M added.
  • The largest Karyopharm Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2023.